Acyclovir (ACV) is used clinically to treat herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. It is selectively phosphorylated in herpesvirus-infected cells. The fully activated drug, ACV triphosphate (ACV-TP), competes with dGTP for binding to the target enzyme, herpesvirus DNA polymerase (recently reviewed in references 11 and 17). Because HSV and VZV code for unusual ribonucleotide reductases that are not subject to the customary allosteric product inhibition of the mammalian counterpart enzymes (5, 6, 20), they induce the unrestricted synthesis of deoxynucleotides (reviewed in references 13 and 14). Consequently, HSV (and presumably VZV)-infected cells treated with ACV develop increased pools of dGTP, which could impede the binding of ACV-TP to herpesvirus DNA polymerases (3, 16, 18). We therefore studied inactivators of herpesvirus ribonucleotide reductases as a means of preventing the buildup of dGTP. Surprisingly, these inactivators not only decreased the dGTP pools but also markedly increased the pools of ACV-TP, thereby enhancing the ACV-TP/dGTP ratio by 90-fold (16, 18). Thus, 2-acetylpyridine-4-(2-morpholinoethyl)thiosemicarbazone (A723U), an inactivator of herpesvirus ribonucleotide reductases, potentiates the antiviral activity of ACV in vitro (7, 16) 
subsequently found to cause hematological toxicity at high oral doses in rats. Eleven structurally related inactivators of herpes simplex virus (HSV) ribonucleotide reductase were therefore tested in vivo for hematological toxicity and for potentiation of ACV. None of the novel ribonucleotide reductase inactivators was hematologically toxic to rats following oral dosing at 60 mg/kg/day for 30 days. Four of these inactivators statistically improved the antiviral topical potency of ACV on HSV type 1-infected nude mice. A promising compound, 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl]thiocarbonohydrazone (BW 348U87), was studied more extensively in two in vivo models: dorsum-infected athymic nude mice and snout-infected hairless mice. BW 348U87 significantly potentiated the antiviral activity of ACV against all virus strains tested, i.e., wild-type (ACV-sensitive) HSV type 1 and HSV type 2 strains and three mutant (ACV-resistant) HSV type 1 strains. The latter included a virus expressing a DNA polymerase resistant to inhibition by ACV triphosphate, a virus deficient in thymidine kinase (the enzyme responsible for phosphorylating ACV), and a virus expressing an altered thymidine kinase, which catalyzes the normal phosphorylation of thymidine but not of ACV. BW 348U87 and ACV are currently being developed as a combination topical therapy for cutaneous herpes infections.
Acyclovir (ACV) is used clinically to treat herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. It is selectively phosphorylated in herpesvirus-infected cells. The fully activated drug, ACV triphosphate (ACV-TP), competes with dGTP for binding to the target enzyme, herpesvirus DNA polymerase (recently reviewed in references 11 and 17) . Because HSV and VZV code for unusual ribonucleotide reductases that are not subject to the customary allosteric product inhibition of the mammalian counterpart enzymes (5, 6, 20) , they induce the unrestricted synthesis of deoxynucleotides (reviewed in references 13 and 14). Consequently, HSV (and presumably VZV)-infected cells treated with ACV develop increased pools of dGTP, which could impede the binding of ACV-TP to herpesvirus DNA polymerases (3, 16, 18) . We therefore studied inactivators of herpesvirus ribonucleotide reductases as a means of preventing the buildup of dGTP. Surprisingly, these inactivators not only decreased the dGTP pools but also markedly increased the pools of ACV-TP, thereby enhancing the ACV-TP/dGTP ratio by 90-fold (16, 18) . Thus, 2-acetylpyridine-4-(2-morpholinoethyl)thiosemicarbazone (A723U), an inactivator of herpesvirus ribonucleotide reductases, potentiates the antiviral activity of ACV in vitro (7, 16) (10) , potentiates the antiviral activity of ACV in vivo (2, 8) as well as in vitro (18) .
Unfortunately, in this study, rats dosed orally with BW * Corresponding author.
1110U81 at 60 mg/kg/day for 30 days developed hematological toxicity. Although a topically applied compound would not be expected to expose humans to comparable levels of BW 1110U81, this toxicity was nevertheless undesirable. We therefore sought safer inactivators with similar efficacies. In the present study, a series of compounds that had demonstrated apparently selective inactivation of HSV ribonucleotide reductase (1) were tested for hematological toxicity in rats and for antiviral efficacy in combination with ACV on mice. One hematologically nontoxic and highly efficacious compound, 2-acetylpyridine5-[(2-chloroanilino)thiocarbonyl]thiocarbonohydrazone (BW 348U87), was studied further. The mechanism of inactivation of HSV type 1 (HSV-1) ribonucleotide reductase by BW 348U87 has been reported elsewhere (19) .
MATERIALS AND METHODS Ribonucleotide reductase inactivators. BW 1110U81 was synthesized as previously described (18) . Other inactivators were synthesized in our laboratories (1) .
Hematological toxicity. Groups of five male and five female CD rats (Crl:CDBR VAF/Plus), purchased from Charles River Breeding Laboratories, Inc., Raleigh, N.C., were dosed orally for 30 consecutive days with the compounds listed in Table 1 at 60 mg/kg/day. Test substances were suspended in 0.5% methylcellulose and given by gavage. Complete blood counts without differential cell counts were measured once before dosing, after 2 weeks of dosing, on the last day of dosing, and 30 days after dosing. The evaluated parameters are listed in Table 1 , footnote a. The data were 45 (20) 49 (9) 53 (10)d 23 (5) 41 (10) 61 (9)d 30 (8) 54 (10)d 28 (7) 32 (7) a Rats orally dosed with BW 110U81 had the following changes, compared with untreated animals: hematocrit, 10.5% decrease; hemoglobin, 10% decrease; erythrocyte count, 24% decrease; erythrocyte distribution width, 53% increase. Less than a 10% change occurred in the platelet count and the leucocyte count (relative and absolute).
b Negative, no significant hematological changes (P > 0.05 (2, 8) . BW 348U87 was considered to potentiate or to synergize with ACV when the observed AUC of the combination therapy was significantly smaller than the AUC calculated for the sum of the independent antiviral activities of ACV and BW 348U87.
The latter was calculated from the following equation:
Details of the various experiments with BW 348U87 and ACV are described in Table 2 , footnote a.
Animals and viruses. Athymic nude mice and hairless mice were purchased and caged as described previously (2, 8).
The strains of wild-type and ACV-resistant HSV and their in vitro susceptibilities to ACV have been described previously (8) . Mice were infected on either the dorsum (8) or the snout (2).
RESULTS
Hematological toxicity. BW 111OU81 given to rats by gavage at 60 mg/kg/day for 30 days caused significant hematological toxicity (Table 1) . Eleven new compounds recently found to potently inactivate HSV ribonucleotide reductase (1) did not produce hematological toxicity (Table 1) . Therefore, all eleven inactivators were tested in combination with ACV for antiviral efficacy in vivo.
Antiviral efficacy. Mice infected on the dorsum with wildtype HSV-1 were treated with topical preparations of either 5% ACV or 5% ACV plus 3% inactivator or were untreated. Untreated control mice fully developed "zosteriformlike" rashes in about 7 days. Neither BW 111OU81 (8) 16 days (15 days in experiment 4). In experiment 5, nine hairless mice per group were infected via the snount, treated on days 0.5 to 4 postinfection, and scored for 10 days. The AUC values (standard errors) for the control (untreated) groups for experiments 1 to 5 were 63 (2), 57 (7), 39 (9) , 32 (4), and 24 (2), respectively. The combination therapy was considered enhanced (either synergy or potentiation) when the observed AUC was significantly smaller than the AUC calculated for the sum of the independent antiviral activities of ACV and BW 348U87 (see Materials and Methods). The calculated percent AUC values (standard errors), relative to the controls, for the combination therapy in expreiments 1 to 5 were 47 (7), 76 (10), 40 (20) , 70 (10), and 52 (7), respectively. P values, determined with a two-sample Student's t test, represent the level of significance of the difference between the observed and calculated values. resistant) HSV-1 strains. The latter included a virus (46-fold resistant) expressing a DNA polymerase resistant to inhibition by ACV-TP, a virus (11-fold resistant) deficient in thymidine kinase (the enzyme responsible for phosphorylating ACV), and a virus (14-fold resistant) expressing an altered thymidine kinase, which catalyzes the normal phosphorylation of thymidine but not of ACV. Athymic mice infected on the dorsum (experiments 1 to 4) and hairless mice infected on the snout (experiment 5) were used as models. BW 348U87 significantly potentiated the antiviral efficacy of ACV against all virus strains (Table 2) . BW 348U87 demonstrated statistically significant inherent antiviral activity only against HSV-1 expressing a substrate specificity-altered thymidine kinase. The data from experiments with the DNA polymerase and altered thymidine kinase mutants are shown in Fig. 1 and 2 . No obvious dermal toxicity was observed in any study. Similar results were noted for athymic nude mice infected with the thymidine kinase-altered (ACV-resistant) HSV-1 mutant (data not shown). 
DISCUSSION
BW 1110U81 potentiates or synergizes with ACV as a topical treatment for mice infected with several wild-type and ACV-resistant HSVs (2, 8) . It also produces synergistic inhibition of VZV replication in vitro (18) . Although the present finding that rats developed hematological toxicity when dosed orally with BW 1110U81 at 60 mg/kg/day for 30 days did not prohibit the development of this topical therapy, it did detract from the overall safety profile and prompted us to find a less toxic analog with similar efficacy. Eleven novel compounds were selected for further study on the basis of enzyme studies that identified them as highly potent and relatively selective inactivators of HSV-1 ribonucleotide reductase (1) . Some of these analogs were tested in vitro and found to synergize with ACV in inhibiting HSV-1 and HSV-2 replication (4). As none of the 11 inactivators was hematologically toxic for rats, BW 1110U81 appeared to be the exception rather than the rule for this series of inactivators.
Although the mechanism of hematological toxicity of BW 1110U81 is not known, it is noteworthy that the compounds that were not hematologically toxic contain either an aminophenyl or an aminopyridyl group in place of the dimethylamino group on the terminus of the parent compound. Preliminary data indicate that the phenyl group of BW 348U87 markedly increases its affinity for serum albumin (9) . Thus, if these compounds enter the bloodstream, they would be sequestered by binding to serum albumin. Alternatively, they may not reach toxic levels in blood or, possibly, they simply are not hematologically toxic. In any case, we were encouraged to pursue efficacy studies with infected mice.
Nude mice infected on the dorsum with HSV-1 were treated with each analog in combination with ACV and with ACV alone. On the basis of earlier studies with BW 1110U81 (8), we assumed that the inactivators by themselves had no therapeutic activity in this particular model. Our assumption was supported by the lack of independent activity of BW 348U87 in this HSV-1 zosteriform model (experiment 1 in Table 2 ). Therefore, an inactivator was considered to be a potentiator of ACV when the combination therapy with that inactivator was significantly more effective than therapy with ACV alone. These studies confirmed the potentiation by BW 1110U81 noted earlier and revealed that four other inactivators also significantly potentiated the antiviral activity of ACV (8) . Three additional inactivators produced nearly significant potentiation. BW 348U87, the best potentiator, was selected for additional studies.
BW 348U87 potentiated or synergized with ACV in the two in vivo models studied: dorsum-infected athymic nude mice and snout-infected hairless mice. Statistically significant potentiation occurred against infections by all ACVsensitive and ACV-resistant viral strains. Technically, the potentiation against infections with HSV-1 expressing an altered thymidine kinase was a case of synergy, since both ACV and BW 348U87 independently demonstrated significant antiviral activity in this model.
The present and earlier (2, 8) studies indicate that BW 348U87 and BW 1110U81 have very similar efficacy profiles in vivo. The only minor exception, that BW 1110U81 produced less-than-significant (P = 0.07) potentiation of ACV against the presently studied ACV-resistant virus with an altered DNA polymerase (8) , may be a function of biological variability. Additionally, both compounds inactivate VZV ribonucleotide reductase (18, 19) and potentiate the ability of ACV to inhibit the in vitro replication of VZV (15, 18) . Thus, BW 348U87 has been identified as efficacious and hematologically nontoxic. BW 348U87-ACV is currently being developed as a combination topical therapy for cutaneous herpes infections.
